Evusheld has been granted conditional marketing approval by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022. However, the MHRA highlighted uncertainty over the appropriate dose needed for protection against the Omicron variant. Understanding the efficacy of Evusheld is necessary prior to any procurement or deployment.
The UK Health Security Agency is currently undertaking further testing on the treatment’s effectiveness against the Omicron variant. This will inform any decisions on the potential procurement of this treatment.